SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as traders position ahead of the company's upcoming Q2 earnings report, with retail sentiment shifting to extremely bullish on expectations of a revenue and EPS beat given management's historically conservative guidanceconsensus calls for roughly $145.5 million in quarterly revenue, up more than 12% year over year. The QNX physical-AI narrative is amplifying the buzz: traders highlight NVIDIA's adoption of QNX 8.0 for automotive and physical AI operating systems, a Sift-QNX partnership to stream telemetry from physical AI systems, and speculation that an Alloy Kore win could soon become visible in the roughly $950 million QNX royalty backlog, which management previously said contained no Alloy Kore business. The community remains split, howeveran active short camp repeatedly urges 'short every pop' into the report, some skeptics argue past beats came only from lowered guidance, and longs counter that QNX's embedded-software footprint is deeply undervalued as they watch for a breakout from single-digit prices.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is trending on bullish clinical momentum in pancreatic cancer and a stack of anticipated near-term catalysts. Traders are citing interim data  a 67% complete response rate, 100% local disease control in pancreatic patients, and a Keytruda combination reported at a 100% response rate with median overall survival well above the historical benchmark  along with the IMPACT pancreatic trial wrapping enrollment after expanding from 12 to roughly 50 patients on physician demand. Much of the discussion centers on expected milestones: a pending IDE approval for the Keytruda combination trial that bulls expect imminently, plus upcoming GBM scan readouts and the SCC trial. Secondary chatter covers MSCI index inclusion, the TASE listing, a Barclays price target hike, and the Tolmar commercialization partnership. Sentiment is overwhelmingly bullish, with debate over whether institutions and the broader market are underrating the name, some pointing to persistent short pressure, and others frustrated that strong news has not yet translated into sustained gains.

Securitize Corp. is a financial technology company, which engages in the provision of regulated infrastructure for the issuance, management, trading, and administration of tokenized real-world assets (RWAs). The company was founded on October 17, 2025 and is headquartered in Miami, FL.

Securitize Corp.

Securitize's debut as a public company under its new ticker is driving the conversation, with the community sharply split between a tokenization pure-play thesis and frustration over the stock's weak early tape. Bulls frame SECZ as the only listed pure play on tokenization, citing growth in tokenized assets from $1B to $3.4B, BlackRock/Cantor Fitzgerald ties, a reported 9.6% Hanwha stake making it the largest holder, trader-flagged ARK ETF share purchases, and a Rosenblatt Buy initiation. Traders are also fixated on a small float of roughly 17 million shares and lockup schedules, fueling short-squeeze speculation, while others argue heavy short volume and market-maker hedging—some claim via arbitrage between the NYSE listing and Securitize's own on-chain market—are pressuring the price. Skeptics question the first report as a public company, pressing management on why revenue was deferred to Q3, and point to a ~$1B market cap, thin fundamentals, minimal analyst coverage, and heavy selling as reasons for caution. Sentiment is divided between long-term tokenization adoption and near-term valuation and earnings concerns.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Speculation that Novo Nordisk could pursue a large acquisition or partnership of Viking Therapeutics is dominating the ticker, sparked by Novo's statement that its balance sheet could support deals well beyond the small bolt-ons typical of pharma as it battles Eli Lilly in obesity. Traders repeatedly cast VK2735, Viking's GLP-1/GIP dual agonist viewed as a potential tirzepatide rival, as the asset that would make Viking a logical target, and some link the stock's move to Novo's own slide on pipeline concerns; others argue Big Pharma M&A hype around Viking is overblown. No bid or partnership has been confirmed, so the deal talk remains speculation. Underneath is intense anticipation of VK2735's Phase 3 readouts, which many view as the stock's defining upcoming catalyst: bulls say the lack of a pre-data run-up plus heavy short interest sets up a strong reaction, while bears cite GI tolerability risks, slower planned Phase 3 titration, dilution, and criticism of CEO Brian Lian's communication as setup for a sell-the-news disappointment.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBAR's trending conversation centers on the Senate vote to open debate on the Clarity Act, the crypto market-structure bill that would split SEC and CFTC oversight of digital assets. Traders repeatedly tie the token's attention to that vote and to expectations of new SEC rules for commodity-classified coins including HBAR, but reaction is split: bulls argue it is not the time to sell with regulatory clarity approaching, one trader cautions the vote was only a procedural step to begin debate, and others accuse both parties of stalling for political reasons, naming senators they say voted against advancing the bill. Skeptics dismiss the SEC-news spike as another "carrot on a string" pump, blaming market manipulation for the quick fade and the token's failure to reclaim the $0.08 area, while technical posters point to the 200 MA near $0.068 and an oversold RSI. A smaller group of traders links the weakness to Grayscale withdrawing its spot HBAR ETF filing, and isolated posts tout Hedera developments such as SpaceDev joining the Hedera Council, but the Clarity Act dominates the discussion.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as traders clash over the stock's repeated failure to hold gains and clear the ~$50 area even as the Nasdaq rallies: longs point to elevated short interest and squeeze potential while alleging market-maker suppression, and other traders are shorting the name outright. The debate is framed around IREN's Bitcoin-mining-to-AI/HPC data-center pivot, which bulls cite as the long-term growth story behind their conviction.

Maase, Inc. operates as a integrated provider and operator of artificial intelligence (AI) centric full-scene digital systems. The firm focus on areas of flexible energy deployment and intelligent commercial network operation, and provide closed-loop solutions from computing infrastructure, smart hardware and full-scene services, aiming to achieve large-scale implementation of AI technologies across industries. The company was founded by Hai Feng Yu on August 6, 2018 and is headquartered in Qingdao, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

Maase Inc. (MAAS), the China-based AI company formerly known as Highest Performances Holdings, is drawing attention for a steady stream of contract announcements around its token-based AI services business. Traders repeatedly cite a RMB1.65M contract with completed client acceptance and full payment, a RMB10M-plus Zhongchuang Liankong enterprise AI deal targeted for Q3 delivery, an RMB7.68M signing, and company claims that its Lingyan Miaoyu LLM is generating B2B revenue  which bulls read as evidence the AI pivot is producing real revenue and clean execution rather than just headlines. The conversation splits between bulls highlighting the repeatable news flow alongside a chart they describe as consolidating above key moving averages with expanding volume, and cautious traders asking why the stock still sold off after positive news and waiting for price-and-volume confirmation and short-interest data before chasing. Smaller threads cover the AI security white paper, its energy-delivery and mobile-robot initiatives, and a national entrepreneurship competition award.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

AVAX is trending after a sharp rally that caught much of the community off guard, with many traders asking why the token is up so much while others celebrate positions moving back toward break-even. Bulls frame the move as the start of a broader altcoin rotation  noting AVAX outpaced Bitcoin's percentage gains  and point to an SEC tokenization decision, Charles Schwab adding AVAX alongside SOL and LINK to its brokerage platform, and institutional tokenization builds on Avalanche such as Hanwha's as fundamental support. Regulatory chatter around SEC/CFTC rulemaking and the stalled Clarity Act also runs through the discussion. Skeptics call the chart an obvious pump-and-dump, argue the token keeps lagging despite positive headlines while the sector sits near 52-week lows, and say they are shorting the pumps. Some traders also flag a potential Avalanche tokenomics update as a future catalyst.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is trending after the S&P 500 staged a sharp rally to fresh highs, with traders flagging a first close above the 765.41 level, a push toward 775, and key levels set at 771/768 support with 781 as the main target. The dominant conversation is a heated debate over what drove the move and whether it lasts: many attribute the surge to a short squeeze or gamma-driven options flows forcing dealers to buy, while others dismiss it as options-market manipulation with no fundamental catalyst, noting the move wasn't confirmed by dark pool buying. Some traders credit momentum after a 0.25% Fed rate hike that delivered the policy certainty bulls wanted; others point to AI-related tech strength carrying the Nasdaq to record highs, and a few tie the bid to easing geopolitics after an Iranian offer to reopen the Strait of Hormuz. Skeptics call it an over-extended blow-off top  "only fools will buy here"  with several saying they are positioned or waiting to short, while breadth concerns (equal-weight indexes lagging the tech-heavy rally and more new lows than new highs near a record) fuel bubble talk. Bulls counter that the market "is not going to pull back" and see room for another ~2% advance, even as traders share a story of Fed official Musalem calling for more rate hikes to curb inflation.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

On Holding's Q2 report is the focal point of the discussion: revenue of CHF 850.3M missed the CHF 879.57M consensus (with EPS of CHF 0.35 a hair above the CHF 0.34 consensus) and a growth-guidance cut that management framed as protecting "price integrity," triggering a record single-day drop and pushing the stock to 52-week lows. The community is sharply divided: bulls call the selloff a major overreaction for a company they say is compounding at 20%+ in an industry growing barely 1%, with best-in-class margins, a Rule-of-40 profile and a generally Buy/Strong Buy analyst consensus; bears counter that the guidance cut amounts to an admission that demand was softer than priced in, flagging customer inventory glut, fad/competition risks, and management credibility concerns after burned targets this year. A number of traders also frame the weakness as sector-wide, noting consumer/apparel peers like Nike, Deckers and Lululemon are struggling amid industry-wide discounting, while others insist On is the exception in a barely-growing industry. Attention is also on two fresh developments being weighed against the guidance damage: On's investor-day unveiling of its "Next Chapter" strategy with 2029 financial targets and a $1 billion buyback  met with skepticism from traders who see multi-year, conservative targets as promises to rebuild trust rather than upside  and the signing of Kylian Mbapp away from Nike, On's push into soccer that splits analysts over whether the sponsorship cost will pay off.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$WLTH CEO dumping shares is always a good sign 😂😂

StockTwits for iOS

Wealthfront Corp.

 CEO dumping shares is always a good sign 😂😂